Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-paclitaxel + carboplatin versus epirubicin + docetaxel as neoadjuvant therapy for triple-negative breast cancer
ChiCTR1900026499Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of paclitaxel, carboplatin, epirubicin and docetaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Pathologic complete remission rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatinepirubicindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1900026499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026499.